These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22224594)

  • 1. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
    Prime ME; Andersen OA; Barker JJ; Brooks MA; Cheng RK; Toogood-Johnson I; Courtney SM; Brookfield FA; Yarnold CJ; Marston RW; Johnson PD; Johnsen SF; Palfrey JJ; Vaidya D; Erfan S; Ichihara O; Felicetti B; Palan S; Pedret-Dunn A; Schaertl S; Sternberger I; Ebneth A; Scheel A; Winkler D; Toledo-Sherman L; Beconi M; Macdonald D; Muñoz-Sanjuan I; Dominguez C; Wityak J
    J Med Chem; 2012 Feb; 55(3):1021-46. PubMed ID: 22224594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.
    Schaertl S; Prime M; Wityak J; Dominguez C; Munoz-Sanjuan I; Pacifici RE; Courtney S; Scheel A; Macdonald D
    J Biomol Screen; 2010 Jun; 15(5):478-87. PubMed ID: 20395409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
    Mastroberardino PG; Iannicola C; Nardacci R; Bernassola F; De Laurenzi V; Melino G; Moreno S; Pavone F; Oliverio S; Fesus L; Piacentini M
    Cell Death Differ; 2002 Sep; 9(9):873-80. PubMed ID: 12181738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinnamoyl inhibitors of tissue transglutaminase.
    Pardin C; Pelletier JN; Lubell WD; Keillor JW
    J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
    Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
    Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
    Grosso H; Mouradian MM
    Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
    Badarau E; Collighan RJ; Griffin M
    Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
    Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
    J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
    Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
    Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.
    Tatsukawa H; Kojima S
    Cell Biol Int; 2010 Feb; 34(3):325-34. PubMed ID: 20192918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
    Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
    Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
    Menalled LB; Kudwa AE; Oakeshott S; Farrar A; Paterson N; Filippov I; Miller S; Kwan M; Olsen M; Beltran J; Torello J; Fitzpatrick J; Mushlin R; Cox K; McConnell K; Mazzella M; He D; Osborne GF; Al-Nackkash R; Bates GP; Tuunanen P; Lehtimaki K; Brunner D; Ghavami A; Ramboz S; Park L; Macdonald D; Munoz-Sanjuan I; Howland D
    PLoS One; 2014; 9(6):e99520. PubMed ID: 24955833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.
    Mastroberardino PG; Piacentini M
    J Intern Med; 2010 Nov; 268(5):419-31. PubMed ID: 20964734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
    Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
    Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement.
    Strnad P; Harada M; Siegel M; Terkeltaub RA; Graham RM; Khosla C; Omary MB
    Gastroenterology; 2007 Apr; 132(4):1515-26. PubMed ID: 17408647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD; Johnson GV
    Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
    Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
    J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.
    Eastwood P; Gonzalez J; Paredes S; Nueda A; Domenech T; Alberti J; Vidal B
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1697-700. PubMed ID: 20137946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of cystamine in a murine model of Huntington's disease.
    Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
    J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.